RT @KNVokinger: Amount of drugs approved for multiple indications and approved as combination regimens has increased. Should indications be…
RT @NatRevClinOncol: In a Comment now online, @KNVokinger and @akesselheim from @uzh_en and @PORTAL_research propose new approaches to nego…
RT @KNVokinger: Amount of drugs approved for multiple indications and approved as combination regimens has increased. Should indications be…
Value-based pricing of drugs with multiple indications or in combinations — lessons from Europe https://t.co/4NxjM1BPSO
Amount of drugs approved for multiple indications and approved as combination regimens has increased. Should indications be reimbursed at single price level when degree of value might vary? Our implications in @NatRevClinOncol @UZH_ch @PORTAL_Research h
In a Comment now online, @KNVokinger and @akesselheim from @uzh_en and @PORTAL_research propose new approaches to negotiate drug prices, with examples from European countries @NatResCancer https://t.co/jotj6Nrqur https://t.co/0raEE8W3YB